Estimation of world seroprevalence of SARS-CoV-2 antibodies
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Global COVID-19 antibody prevalence was estimated using serosurveys, vaccination data, and national statistics. Bayesian models addressed data gaps, revealing significant population immunity by July 2021.
Area Of Science
- Epidemiology
- Immunology
- Biostatistics
Background
- Estimating global COVID-19 seroprevalence is crucial for understanding population immunity.
- Existing serosurveys have limitations, including geographical gaps and varied sample collection dates.
Purpose Of The Study
- To estimate country-specific and global COVID-19 seroprevalence.
- To address challenges in seroprevalence estimation due to missing survey data and temporal discrepancies.
Main Methods
- Utilized Bayesian hierarchical models to estimate antibodies from infection, integrating confirmed cases and national statistics.
- Employed regression models to impute missing vaccination data.
- Combined serosurvey data with modeled estimates for comprehensive global coverage.
Main Results
- Estimated global seroprevalence by July 31, 2021, providing a credible interval.
- Successfully addressed data gaps in serological surveys and vaccination records.
Conclusions
- The developed methodology provides a robust framework for estimating global seroprevalence.
- The findings offer valuable insights into population immunity against COVID-19 worldwide.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.